Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
225 articles with Portola Pharmaceuticals, Inc.
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
The U.S. Food and Drug Administration (FDA) approved Portola Pharmaceuticals’ Andexxa, an antidote for blood thinners rivaroxaban and apixaban.
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
Shares of Portola Pharmaceuticals are falling after the company announced a delay of several months for possible regulatory approval of its Factor Xa-inhibitor antidote, AndexXa.
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
The data will be presented on Monday, March 12, 2018 at 11:30 a.m. ET.
1/15/2018Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
The FDA communicated that the action date will move from February 3, 2018 to May 4, 2018.
The FDA continues to hand out some early Christmas presents to pharma companies.
Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban
The CHMP has provided the Day 195 List of Outstanding Issues (LoOI) to the company with a request for responses during the next available submission window of January 23, 2018.
Portola granted to Mr. Lawrence an award in the form of 5,000 restricted stock units.
The new action date is January 30, 2018.
Collaboration and license revenue earned was $3.8 million for the third quarter of 2017, compared with $9.3 million for the third quarter of 2016.
Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and Chief Medical Officer
Dr. Lawrence will report to William Lis, chief executive officer, and will be responsible for leading all product development, as well as clinical strategies.
Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6
The company will host a webcast and conference call to discuss the company’s financial results the same day.
Reminder: Portola To Host Webcast And Conference Call Today, Tuesday, Sept. 5 To Provide Further Details On Bevyxxa (Betrixaban) Launch
Portola Announces Andexxa (Andexanet Alfa) Biologics License Application Resubmission Accepted For Review By U.S. FDA